the two drugs are structurally related, their in vitro activities differ rather significantly (1, 2) . Against members of the family Enterobacteriaceae, cefotetan is much more active than cefoxitin, but cefoxitin is generally more active against most gram-positive cocci. The pharmacokinetic properties of the two drugs also differ. Levels of cefotetan in blood are elevated, and the elimination half-life is prolonged (5) . Because of differences in the achievable levels in blood, the MIC breakpoint which defines the susceptible category for cefotetan is one doubling dilution greater than that for cefoxitin (<16 Rg of cefotetan per ml versus .8.0 ,ug of cefoxitin per ml) (4) . Now that cefotetan has been released for clinical use in the United States, clinical laboratories are being asked to perform susceptibility tests. Unfortunately, some manufacturers of antimicrobial susceptibility testing systems have not yet completed the studies necessary to permit them to incorporate cefotetan into their test systems. Since cefoxitin can be tested in those systems, we wanted to know how accurately cefotetan susceptibility or resistance could be predicted from the results of cefoxitin susceptibility test results. In vitro data were collected from 14 institutions, and cefoxitin MICs were compared with cefotetan MICs. As a result of this evaluation, we propose an interim solution to this problem.
The following investigators contributed data which were added to those generated in our own institute: A. e The eight isolates resistant to both drugs were S. pneumoniae.
times more potent than cefotetan. We excluded methicillinresistant staphylococci from our studies because they should be assumed to be resistant to the cephalosporins, regardless of the results of tests with standard methods (4). Twenty methicillin-resistant strains were excluded, and three falsesusceptible results were observed with cefoxitin; all twenty strains were appropriately resistant to cefotetan (data not shown). Of the 75 Streptococcus pneumoniae strains, 8 were resistant to both cephalosporins; they were also resistant or relatively resistant to benzylpenicillin. The other streptococci were susceptible to both cephalosporins. The MICs were categorized by applying the interpretive breakpoints of the National Committee for Clinical Laboratory Standards (4); those categories are compared in Table 2 . Among the 2,255 enteric bacilli that were tested, 1,252 (55.5%) were susceptible to cefoxitin and 807 (35.8%) were resistant to cefoxitin. Only 196 strains (8.7%) were intermediate in susceptibility to cefoxitin (MIC, 16 ,ug/ml). Six of the 1,252 cefoxitin-susceptible strains were reported to be resistant to cefotetan. Five of those six aberrant results were reported by 1 of the 14 participants. Unfortunately, the validity of those six tests could not be confirmed. In the past 3 years, we have evaluated both drugs against more than 1,000 enteric bacilli and have never found a strain which was confirmed to be cefoxitin susceptible but cefotetan resistant. The predictive value of a susceptible test with cefoxitin was 99.3%, i.e., 1,243 of 1,252 strains were also susceptible to cefotetan. The same predictive value was calculated when a cefoxitin MIC of '16 ,ug/ml (intermediate or susceptible category) was used to predict cefotetan MICs of s16 ,ug/ml (susceptible category). Among 807 cefoxitin-resistant enteric bacilli, only 284 strains were also resistant to cefotetan (35.2% predictive value). Among the gram-positive cocci that were tested, only eight S. pneumoniae isolates were resistant to both drugs. None of the cefoxitin-susceptible strains were resistant to cefotetan; 437 of 446 cefoxitinsusceptible strains were susceptible to cefotetan (98% predictive value).
In summary, when members of Enterobacteriaceae, streptococci, or methicillin-susceptible staphylococci are tested, cefoxitin-susceptible strains can be assumed to be susceptible to cefotetan, but cefoxitin-resistant enteric bacilli are not necessarily resistant to cefotetan.
